22 January 2024
Latham & Watkins Advises Coherus BioSciences in Divestment of Ophthalmology Franchise to Sandoz
Advising firms
Deal team
23 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Josh Dubofsky Lead | Latham & Watkins LLP | Partner | M&A | Bay Area |
| Jekkie Kim Lead | Latham & Watkins LLP | Partner | healthcare IP | Bay Area |
| Ben Potter Lead | Latham & Watkins LLP | Partner | emerging companies and growth | Bay Area |
| Phillip Stoup Lead | Latham & Watkins LLP | Partner | capital markets | Bay Area |
| Danny Nordstrom | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Christopher Lim | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Avery Brust | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Chelsi DeTurk | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Fiona Gillan | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Billy Wu | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Grace Lee | Latham & Watkins LLP | Partner | tax | Bay Area |
| Gregory Conyers | Latham & Watkins LLP | Associate | tax | Not stated |
| Josh Holian | Latham & Watkins LLP | Partner | antitrust | Bay Area |
| Hanna Nunez Tse | Latham & Watkins LLP | Associate | antitrust | Not stated |
| Chris Schott | Latham & Watkins LLP | Partner | healthcare regulatory | Washington, D.C. |
| Nicole Liffrig Molife | Latham & Watkins LLP | Counsel | healthcare regulatory | Washington, D.C. |
| Elizabeth Richards | Latham & Watkins LLP | Partner | FDA regulatory | Washington, D.C. |
| Heather Deixler | Latham & Watkins LLP | Partner | data privacy | Bay Area |
| Mitch Bennett | Latham & Watkins LLP | Associate | data privacy | Not stated |
| Jay Metz | Latham & Watkins LLP | Partner | benefits and compensation | Bay Area |
| Nimra Syed | Latham & Watkins LLP | Associate | benefits and compensation | Not stated |
| Les Carnegie | Latham & Watkins LLP | Partner | CFIUS and sanctions | Washington, D.C. |
| Catherine Hein | Latham & Watkins LLP | Counsel | CFIUS and sanctions | Washington, D.C. |
20 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 170m (US$170 million)
- What the figure measures
- Total transaction value
- Client
- Coherus BioSciences, Inc.Sell-side
- Counterparties
- Sandoz (Buy-side)